New pill shows promise for Tough-to-Treat lymphoma

NCT ID NCT06511895

Completed Disease control Sponsor: Dizal Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested an oral drug called AZD4205 in 57 adults with relapsed or refractory peripheral T-cell lymphoma, a rare blood cancer. The study aimed to see if the drug can shrink tumors and how safe it is. Participants took a capsule once daily in 28-day cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD4205 (an oral drug taken as a capsule once daily)
What this could lead to: If successful, this could provide a new treatment option for people with peripheral T-cell lymphoma that has not responded to prior therapy.
What could go wrong: This is a small, early-phase trial (57 participants) with no comparison group. The drug may not work for many patients, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL T-CELL LYMPHOMA

Contacts and locations

Locations

Anhui Provincial Hospital (The First Affiliated Hospital of USTC)

Hefei, Anhui, China
Beijing Cancer Hospital

Beijing, Beijing Municipality, China
Chongqing Cancer Hospital

Chongqing, Chongqing Municipality, China
Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China
Hainan General Hospital

Haikou, Hainan, China
Henan Cancer Hospital

Zhengzhou, Henan, China
Hunan Cancer Hospital

Changsha, Hunan, China
Jiangsu Cancer Hospital

Nanjing, Jiangsu, China
Peking University Third Hospital

Beijing, Beijing Municipality, China
Ruijing Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China
Shandong Cancer Hospital & Insititution

Jinan, Shandong, China
Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China
The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China
The First Bethune Hospital of Jilin University

Changchun, Jilin, China
The Second Hospital of Anhui Meidcine University

Hefei, Anhui, China
Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, China
West China Hospital of Sichuan University

Chengdu, Sichuan, China
Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.